- Home
- THRD vs SGHT Comparison
THRD vs SGHT Comparison
Compare THRD & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THRD
- SGHT
- Stock Information
- Founded
- THRD 2019
- SGHT 2011
- Country
- THRD United States
- SGHT United States
- Employees
- THRD N/A
- SGHT N/A
- Industry
- THRD Biotechnology: Pharmaceutical Preparations
- SGHT Medical Specialities
- Sector
- THRD Health Care
- SGHT Health Care
- Exchange
- THRD Nasdaq
- SGHT Nasdaq
- Market Cap
- THRD 157.7M
- SGHT 140.1M
- IPO Year
- THRD 2022
- SGHT 2021
- Fundamental
- Price
- THRD $3.45
- SGHT $2.41
- Analyst Decision
- THRD Buy
- SGHT Buy
- Analyst Count
- THRD 3
- SGHT 7
- Target Price
- THRD $14.00
- SGHT $3.83
- AVG Volume (30 Days)
- THRD 435.5K
- SGHT 355.6K
- Earning Date
- THRD 03-25-2025
- SGHT 03-05-2025
- Dividend Yield
- THRD N/A
- SGHT N/A
- EPS Growth
- THRD N/A
- SGHT N/A
- EPS
- THRD N/A
- SGHT N/A
- Revenue
- THRD N/A
- SGHT $79,866,000.00
- Revenue This Year
- THRD N/A
- SGHT $3.09
- Revenue Next Year
- THRD N/A
- SGHT $13.61
- P/E Ratio
- THRD N/A
- SGHT N/A
- Revenue Growth
- THRD N/A
- SGHT N/A
- 52 Week Low
- THRD $3.18
- SGHT $2.17
- 52 Week High
- THRD $16.94
- SGHT $8.45
- Technical
- Relative Strength Index (RSI)
- THRD 30.03
- SGHT 42.11
- Support Level
- THRD $3.36
- SGHT $2.25
- Resistance Level
- THRD $3.65
- SGHT $2.93
- Average True Range (ATR)
- THRD 0.14
- SGHT 0.27
- MACD
- THRD 0.16
- SGHT 0.02
- Stochastic Oscillator
- THRD 35.48
- SGHT 30.92
About THRD Third Harmonic Bio Inc.
Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
About SGHT Sight Sciences Inc.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment.